Liu Ya-Rui, Hu Yang, Zeng Ying, Li Zhi-Xing, Zhang Hai-Bo, Deng Jun-Li, Wang Guo
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P. R. China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.
J Cell Biochem. 2019 Oct;120(10):18041-18052. doi: 10.1002/jcb.29107. Epub 2019 Jul 11.
Owing to the high morbidity and mortality, novel biomarkers in the occurrence and development of colorectal cancer (CRC) are needed nowadays. In this study, the CRC-related datasets were downloaded from the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database. After screening the differentially expressed genes (DEGs) in R software, a total of 238 upregulated and 199 downregulated DEGs were revealed simultaneously. Then the Kaplan-Meier survival analysis and Cox regression analysis were used to reveal the prognostic function of these DEGs. Neurexophilin and PC-esterase domain family member 4 (NXPE4) and prostate androgen-regulated mucin-like protein 1 (PARM1) were two outstanding independent overall survival (OS) and relapse-free survival (RFS) prognostic genes of CRC in TCGA database. We next verified the expression of NXPE4 and PARM1 messenger RNA (mRNA) levels were significantly lower in CRC tumor tissue than in the adjacent noncancerous tissue in our clinical samples, and NXPE4 mRNA expression level was related to the tumor location and tumor size, while PARM1 was related to tumor location, lymph nodes metastasis, and tumor size. This study demonstrated that NXPE4 and PARM1 might be two potential novel prognostic biomarkers for CRC.
由于结直肠癌(CRC)的高发病率和高死亡率,目前需要在其发生和发展过程中寻找新的生物标志物。在本研究中,从基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)数据库下载了与CRC相关的数据集。在R软件中筛选差异表达基因(DEG)后,共同时发现238个上调的DEG和199个下调的DEG。然后使用Kaplan-Meier生存分析和Cox回归分析来揭示这些DEG的预后功能。嗜神经素和PC酯酶结构域家族成员4(NXPE4)以及前列腺雄激素调节的粘蛋白样蛋白1(PARM1)是TCGA数据库中CRC的两个出色的独立总生存(OS)和无复发生存(RFS)预后基因。接下来,我们在临床样本中验证了CRC肿瘤组织中NXPE4和PARM1信使核糖核酸(mRNA)水平明显低于相邻的非癌组织,并且NXPE4 mRNA表达水平与肿瘤位置和肿瘤大小有关,而PARM1与肿瘤位置、淋巴结转移和肿瘤大小有关。本研究表明,NXPE4和PARM1可能是CRC的两个潜在的新型预后生物标志物。